ACRX News 10.68 Acelrx Pharmaceuticals (ACRX)

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Acelrx Pharmaceuticals (ACRX) 10.68 $ACRX

Equities to Watch in the Health Care Sector -- Research on Novadaq Technologies, Quest Diagnostics, Cooper Cos, and AcelRx Pharma
PR Newswire - Tue Apr 15, 11:56AM CDT
The trading session on Monday, April 14, 2014 ended on a higher note as the Dow Jones Industrial Average finished at 16,173.24, up 0.91% and the NASDAQ Composite closed at 4,022.69, up 0.57%. The S&P 500 finished the session 0.82% higher at 1,830.61. The gains were broad based as all the ten sectors finished on a positive note. The S&P 500 Health Care Sector Index finished the day at 648.05, up 0.51%, while the same has declined 3.97% in the last one month. Investor-Edge has initiated coverage on the following equities: Novadaq Technologies Inc. (NASDAQ: NVDQ), Quest Diagnostics Inc. (NYSE: DGX), The Cooper Cos Inc. (NYSE: COO) and AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX). Free technical research on NVDQ, DGX, COO and ACRX can be downloaded upon signing up at:

Acquisitions, Scheduled Earnings Releases, Appointments, Clinical Trials, and Stock Movements - Analyst Notes on Baxter, AcelRx, Synta Pharmaceuticals, Spectranetics, and NuVasive
PR Newswire - Fri Apr 11, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Baxter International Inc. (NYSE: BAX), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Synta Pharmaceuticals Corp. (NASDAQ: SNTA), The Spectranetics Corporation (NASDAQ: SPNC), and NuVasive, Inc. (NASDAQ: NUVA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

AcelRx Pharmaceuticals to Present at the 13th Annual Needham Healthcare Conference
PR Newswire - Fri Apr 04, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, and Timothy E. Morris, CFO, will present a Company update on April 9th. Presentation details are as follows:

Healthcare Companies Report Clinical Study Results, Financial Results and Stock Summaries - Analyst Notes on Endocyte, Ophthotech, AcelRx Pharmaceuticals, bluebird bio, and Cantel Medical
PR Newswire - Wed Mar 26, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Endocyte, Inc. (NASDAQ: ECYT), Ophthotech Corporation (NASDAQ: OPHT), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), bluebird bio, Inc. (NASDAQ: BLUE), and Cantel Medical Corp. (NYSE: CMN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

AcelRx Pharmaceuticals Appoints Timothy E. Morris as Chief Financial Officer
PR Newswire - Tue Mar 25, 6:30AM CDT
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Timothy E. Morris as chief financial officer (CFO). Mr. Morris brings 30 years of professional finance and accounting experience to AcelRx, 18 of those years spent in the role of chief financial officer, most recently operating in this capacity at VIVUS, Inc., a commercial-stage biopharmaceutical company. Mr. Morris will be responsible for managing the company's finance operations, its information systems and human resource and investor relations functions. Jim Welch, who had served as CFO since October 2010, departed the company to pursue other business opportunities.

AcelRx Pharmaceuticals to Participate at the 26th Annual Roth Conference
PR Newswire - Fri Mar 07, 3:45PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will present a Company update at the following conference:

Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

Why AcelRx Pharmaceuticals, Inc. Shares Popped Today
Brian Pacampara, The Motley Fool - Motley Fool - Tue Mar 04, 12:42PM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. What: Shares of specialty drug company AcelRx...

GMO Inside Announces Campaign to Get GMOs Out of Starbucks' Dairy
PR Newswire - Tue Mar 04, 9:00AM CST
Green America's GMO Inside campaign today launched a major push to get Starbucks, America's largest coffee chain with more than 20,000 stores in 62 countries, to serve only organic milk sourced from cows not fed GMOs. In early January, GMO Inside made worldwide headlines when its social media campaign led General Mills to announce that it would drop genetically modified ingredients in basic Cheerios.

AcelRx Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Mon Mar 03, 3:05PM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and twelve months ended December 31, 2013.

AcelRx Pharmaceuticals to Hold Fourth Quarter and Annual 2013 Financial Results Conference Call and Webcast on Monday, March 3, 2014
PR Newswire - Mon Feb 24, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2013 financial results after market close on Monday, March 3, 2014. AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) on March 3, 2014 to discuss the financial results and provide a corporate update.

PAREXEL Simplifies Drug Development Journey From Science To New Treatments
PR Newswire - Wed Feb 12, 5:00AM CST
As the global biopharmaceutical industry increasingly seeks to streamline the complex process of bringing new drugs to market, PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services provider, today announced the launch of a new marketing initiative that highlights the Company's proven approach to help clients simplify the journey from science to new treatments.

Mallinckrodt Beats Q1 Earnings, Ups View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 9:35AM CST
Mallinckrodt beats Q1 earnings estimates.

AcelRx Pharmaceuticals to Participate in Three Upcoming Investor Events
PR Newswire - Wed Feb 05, 6:30AM CST
AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO will be presenting a Company update at three upcoming investor conferences. Details of the three events are as follows:

Cempra (CEMP) Falls: Stock Plunges 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Jan 28, 7:47AM CST
Cempra's shares fell nearly 11% yesterday, continuing the most recent downtrend for CEMP, as the stock is down almost 16% since Jan 10.

Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Jan 13, 6:19AM CST
Is AcelRx Pharmaceuticals Inc (ACRX) Ready to Breakout?

Clinical Findings Presentations, Stock Price Movements, and Addition to Indexes - Research Report on Acceleron, AcelRx, Antares, Chelsea Therapeutics, and Clovis
PR Newswire - Mon Jan 06, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Acceleron Pharma, Inc. (NASDAQ: XLRN), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Antares Pharma Inc. (NASDAQ: ATRS), Chelsea Therapeutics International Ltd. (NASDAQ: CHTP), and Clovis Oncology, Inc. (NASDAQ: CLVS). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Drug Availability, Clinical Trial Partnerships, Labeling Discussions, Stock Updates, and Credit Facilities - Research Report on Forest Laboratories, Oxygen Biotherapeutics, Alimera, pSivida and AcelRx
PR Newswire - Tue Dec 24, 7:00AM CST
Editor Note: For more information about this release, please scroll to bottom.

This Guy Used Reddit to Build a Crowdsourced Stock Portfolio. The Results Were Actually Not Bad ...
Jay Jenkins, The Motley Fool - Motley Fool - Sun Dec 22, 9:36AM CST
Late last year, Reddit user PhantomPumpkin began building a simulated portfolio . Over a three-week period, he invested $10,000 in play money into any stock talked about positively on the subreddit r/investing.  Is this a viable portfolio building...

Nasdaq stocks posting largest percentage increases
AP - Thu Dec 19, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PEGATRON Unveils AI and HPC Advances at SC26

Updated Category News Views 128

Revamping AI with High-Density Computing You know, back in the day, AI was just about training models and running basic inference. But now, it's all about these crazy agentic AI tasks—autonomous agents doing things I couldn't have imagined. PEGATRON's Evolution in Infrastructure PEGATRON's latest move at SC26 is a real leap forward in this ongoing AI saga. They're...

Continue Reading
Memorial Manor's Five-Star Signal in Long-Term Care

Updated Category News Views 81

Care quality is the only score that matters here A nursing home recognition is not the sort of news anybody should read like a trophy-case press release and then forget by lunch. Families make decisions around long-term care when they are tired, worried, and often dealing with a parent or spouse whose needs have changed fast. In that setting, a facility putting up both a...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 317

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Teamsters Ratify Contract, Averting Waste Strike

Updated Category News Views 141

Big Win for Teamsters Local 350 You ever seen a strike averted by sheer willpower and unity? That’s what's happened here with the workers at South San Francisco Scavenger Company. These folks—drivers, mechanics, sorters, and utility workers—all banded together under the Teamsters Local 350 and showed management what's what by securing a contract they deserve. We're...

Continue Reading
CD Rates Offer Stillness as Stocks and Gold Wobble

Updated Category News Views 47

November has delivered the sort of tape that makes a supposedly diversified portfolio feel like a leaky boat. Stocks fell sharply, gold slid to a one-year low after record highs as recently as January, and Treasuries have not provided the dependable ballast many investors expected. When inflation worries and federal-debt concerns shove yields higher, bond prices can drop...

Continue Reading
Thoughts Unleashed Arrives With a Personal American Voice

Updated Category News Views 81

A lifetime of observation finally gets its own page Forty is an unusual age to begin writing poetry, which is exactly why Joyce Ann Grooms McGeehan's debut has a little more texture than the usual polished promise of inspiration. Thoughts Unleashed by an Independent, American Woman comes from someone who spent decades teaching French, English, and ESL, then retired to a...

Continue Reading
Toledo Crosswalk Death Lawsuit Raises Hard Questions

Updated Category News Views 144

A painted crosswalk is supposed to mean something, and that is the grim center of the lawsuit filed over Judy Tanner’s death in Toledo. Tanner, 20, was walking home from work on September 10, 2026, when she was struck and killed while crossing the street. Her estate is now suing, alleging that the 31-year-old driver failed to yield as Tanner legally used the crosswalk....

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Fuel Cell Market Faces Uneven Growth Amid Revenue Shifts

Updated Category News Views 144

Fuel Cell Sector Eyes Mixed Results and Big Projections The fuel cell market, oh what a beast it's becoming—a story filled with ups and downs, and more forecasts than a weather station. As we stand, this sector is poised to balloon to an $18.16 billion market by 2030. That's a growth rate of 26.3% annually, folks. These projections are driving excitement, but the...

Continue Reading
Inhabit Puts AI Across Its Property Management Stack

Updated Category News Views 37

Property managers do not need another shiny chatbot; they need fewer dropped leads, fewer invoice-entry mistakes and less staff time burned chasing routine answers. That is the sensible hook in Inhabit's OPTECH 2026 announcement. The company is spreading AI, integrations and scalability work across ResMan, Anyone Home, ePremium, Nationwide Compliant and several adjacent...

Continue Reading

Top 5 Most Recently Viewed Articles

Skylark Labs Enhances Mobility Analytics with New Contracts

Updated Category News Views 259

Transforming Mobility Analytics Skylark Labs is at the forefront of innovation as it takes significant strides to transform mobility analytics. The company recently announced its success in securing multiple contracts aimed at deploying its advanced Scout Towers throughout busy highways. Empowering the Indiana DOT The focus of these contracts is primarily on empowering...

Continue Reading
Arm Collaborates with Malaysia on $250 Million Chip Initiative

Updated Category News Views 201

Introduction to the Exciting Partnership Arm Holdings – ADR (NASDAQ: ARM), a dynamic subsidiary of SoftBank Group Corp. (OTC: SFTBY), has embarked on a groundbreaking partnership with Malaysia, sealing a monumental $250 million deal. This agreement aims to significantly enhance chip design and technology services over the next decade, marking a pivotal moment in both...

Continue Reading
Music Licensing, Inc. (OTC: SONG) Implements New Share Classes

Updated Category News Views 119

Music Licensing, Inc. Unveils New Share Classes and Forward Stock Split Music Licensing, Inc. (OTC: SONG), a well-known leader in music rights management, is making substantial moves to improve its stock market standing. Recently, the company faced some challenges, including an unsuccessful reverse stock split. In response to these hurdles, they are proactively addressing...

Continue Reading
Exploring Legal Actions for Venture Global, Inc. Investors

Updated Category News Views 368

Latest Developments for Venture Global, Inc. Investors Venture Global, Inc. is currently under scrutiny as a class-action lawsuit has been initiated on behalf of its investors. This follows significant developments surrounding the company's operations and interactions with major clients. Understanding the Class Action Lawsuit The lawsuit focuses on the concerns raised by...

Continue Reading
STL and Colt Together Pioneer Multi-Core Fibre Trials for The Future

Updated Category News Views 112

Innovation in Optical Connectivity: The STL and Colt Collaboration In a groundbreaking development, STL (NSE: STLTECH), a renowned connectivity solutions provider, has successfully partnered with Colt Technology Services to conduct trials of their innovative Multi-Core Fibre (MCF). This initiative, executed within Colt's expansive optical network in an urban setting,...

Continue Reading